RafaelCanadas-ZizziasMD Certified Physician Investigator

Internal Medicine • Dallas, TX

Preventive Medicine, Endocrinology, Obesity Medicine & Nutrition

Medical Director at Galenos Research

Join to view full profile

Dr. Canadas-Zizzias is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Canadas-Zizzias' full profile

Already have an account?

Office
12201 Merit Drive
Suite 180
Dallas, TX 75251
Phone+1 972-385-9700

Fax+1 972-385-9790
Is this information wrong?

Education & Training

Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 1994 - 1996
New York-Presbyterian/QueensInternship, Internal Medicine, 1993 - 1994
National University of Cuyo School of MedicineClass of 1990

Certifications & Licensure

TX State Medical License 1997 - 2024
TX State Medical License 1996 - 2024
MI State Medical License 1996 - 1997
American Board of Internal Medicine Internal Medicine
Association of Clinical Research ProfessionalsCertified Physician Investigator

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry

Clinical Trials

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin Start of enrollment: 2002 Mar 01
Completed
Phase 3
Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease Start of enrollment: 2004 Sep 01
Terminated
Phase 4
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Extension Study for 2993-112 Start of enrollment: 2002 Sep 01
Completed
Phase 3
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes Start of enrollment: 2020 May 29
Active, not recruiting
Phase 3
Investigational Study of Delayed Release Metformin Start of enrollment: 2021 May 18
Suspended
Phase 3
Join now to see all

Publications & Presentations

PubMed

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DC, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JP, SCALE Obesity and Prediabetes NN8022-18...> ;The New England journal of medicine.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Rossing P, Burgess E, Agarwal R, Anker SD, Filippatos G, Pitt B, Ruilope LM, Gillard P, MacIsaac RJ, Wainstein J, Joseph A, Brinker M, Roessig L, Scott C, Bakris GL, F...> ;Diabetes care.
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM, FIGARO-DKD Investigators> ;The New England journal of medicine. 2021-08-28
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G, FIDELIO-DKD Investigators> ;The New England journal of medicine. 2020-10-23
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM, Agarwal R, Anker SD, Bakris GL, Filippatos G, Nowack C, Kolkhof P, Joseph A, Mentenich N, Pitt B, FIGARO-DKD study investigators> ;American journal of nephrology. 2019-10-30
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G, on behalf of the FIDELIO-DKD study investigators, FIDE...> ;American journal of nephrology. 2019-10-25
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, R...> ;The New England journal of medicine. 2017-09-14
379 citations
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
Carel W. le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C.W. Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine Vang Skjøth, Linda Shapiro Man...> ;Lancet. 2017 Apr 8
Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5.
Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J, Hartman ML, Carey MA, Chang AM, IMAGINE 5 Investigators> ;Diabetes care. 2015-11-17
Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-la...
Gough SC, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P, Damgaard LH, Buse JB, NN9068-3697 (DUAL-I) trial investigators> ;The lancet. Diabetes & endocrinology. 2014-09-01
Join now to see all